Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 9879087 Glycan-interacting compounds and methods of use

Patent 9879087 was granted and assigned to Siamab Therapeutics, Inc. on January, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

All edits

Edits on 27 Dec, 2023

"update inverses"

edited on 27 Dec, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

US Patent 11850262 Compositions and methods for CAR T cell therapy

0

Edits on 7 Dec, 2023

"Add patent abstract"

edited on 7 Dec, 2023

Edits made to:

Article (+460 characters)

Article

Patent abstract

The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.

Edits on 11 Oct, 2023

"update inverses"

edited on 11 Oct, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

US Patent 11779602 Methods of use for CAR T cells

Edits on 20 Sep, 2023

"update inverses"

edited on 20 Sep, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

US Patent 11759480 Compositions and methods for CAR T cell therapy

Edits on 26 Jul, 2023

"update inverses"

edited on 26 Jul, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

US Patent 11708572 Acoustic cell separation techniques and processes

0

Edits on 5 Jul, 2023

"update inverses"

edited on 5 Jul, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

US Patent 11692039 Multifunctional natural killer (NK) cell engagers binding to NKp46 and CD123

0

Edits on 20 May, 2023

"Remove leading 0 from patent number"

edited on 20 May, 2023

Edits made to:

Infobox (+1/-1 properties)

‌

US Patent 09879087 Glycan-interacting compounds and methods of use US Patent 9879087 Glycan-interacting compounds and methods of use

Infobox

Patent Number

0987908700

Patent Number

987908700

Edits on 24 Apr, 2023

"Entity importer update"

edited on 24 Apr, 2023

Infobox

Is a

0

Patent Applicant

Siamab Therapeutics, Inc.

0

Current Assignee

Siamab Therapeutics, Inc.

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

098790870

Date of Patent

January 30, 2018

0

Patent Application Number

149874320

Date Filed

January 4, 2016

0

Patent Primary Examiner

Stephen Rawlings

0

Edits on 24 Sep, 2022

"Entity importer update"

edited on 24 Sep, 2022

Infobox

Is a

0

Patent Applicant

Siamab Therapeutics, Inc.

0

Current Assignee

Siamab Therapeutics, Inc.

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

098790870

Date of Patent

January 30, 2018

0

Patent Application Number

149874320

Date Filed

January 4, 2016

0

Patent Primary Examiner

Stephen Rawlings

0

Edits on 16 Jan, 2022

"Created via: Entity Importer"

created this topic on 16 Jan, 2022

Edits made to:

Infobox (+9 properties)

‌

US Patent 09879087 Glycan-interacting compounds and methods of use

Infobox

Is a

Patent applicant

Siamab Therapeutics, Inc.

Current assignee

Siamab Therapeutics, Inc.

Patent jurisdiction

United States Patent and Trademark Office

Patent number

09879087

Date of patent

January 30, 2018

Patent application number

14987432

Date Filed

January 4, 2016

Patent primary examiner

Stephen Rawlings

Find more entities like US Patent 9879087 Glycan-interacting compounds and methods of use

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.